Reward deficiency syndrome: genetic aspects of behavioral disorders
- PMID: 11105655
- DOI: 10.1016/S0079-6123(00)26022-6
Reward deficiency syndrome: genetic aspects of behavioral disorders
Abstract
The dopaminergic and opioidergic reward pathways of the brain are critical for survival since they provide the pleasure drives for eating, love and reproduction; these are called 'natural rewards' and involve the release of dopamine in the nucleus accumbens and frontal lobes. However, the same release of dopamine and production of sensations of pleasure can be produced by 'unnatural rewards' such as alcohol, cocaine, methamphetamine, heroin, nicotine, marijuana, and other drugs, and by compulsive activities such as gambling, eating, and sex, and by risk taking behaviors. Since only a minority of individuals become addicted to these compounds or behaviors, it is reasonable to ask what factors distinguish those who do become addicted from those who do not. It has usually been assumed that these behaviors are entirely voluntary and that environmental factors play the major role; however, since all of these behaviors have a significant genetic component, the presence of one or more variant genes presumably act as risk factors for these behaviors. Since the primary neurotransmitter of the reward pathway is dopamine, genes for dopamine synthesis, degradation, receptors, and transporters are reasonable candidates. However, serotonin, norepinephrine, GABA, opioid, and cannabinoid neurons all modify dopamine metabolism and dopamine neurons. We have proposed that defects in various combinations of the genes for these neurotransmitters result in a Reward Deficiency Syndrome (RDS) and that such individuals are at risk for abuse of the unnatural rewards. Because of its importance, the gene for the [figure: see text] dopamine D2 receptor was a major candidate gene. Studies in the past decade have shown that in various subject groups the Taq I A1 allele of the DRD2 gene is associated with alcoholism, drug abuse, smoking, obesity, compulsive gambling, and several personality traits. A range of other dopamine, opioid, cannabinoid, norepinephrine, and related genes have since been added to the list. Like other behavioral disorders, these are polygenically inherited and each gene accounts for only a small per cent of the variance. Techniques such as the Multivariate Analysis of Associations, which simultaneously examine the contribution of multiple genes, hold promise for understanding the genetic make up of polygenic disorders.
Similar articles
-
Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors.J Psychoactive Drugs. 2000 Nov;32 Suppl:i-iv, 1-112. doi: 10.1080/02791072.2000.10736099. J Psychoactive Drugs. 2000. PMID: 11280926 Review.
-
Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: part 2.Postgrad Med. 2010 Nov;122(6):214-26. doi: 10.3810/pgm.2010.11.2237. Postgrad Med. 2010. PMID: 21084796 Clinical Trial.
-
Acute intravenous synaptamine complex variant KB220™ "normalizes" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports.Postgrad Med. 2010 Nov;122(6):188-213. doi: 10.3810/pgm.2010.11.2236. Postgrad Med. 2010. PMID: 21084795 Review.
-
Do dopaminergic gene polymorphisms affect mesolimbic reward activation of music listening response? Therapeutic impact on Reward Deficiency Syndrome (RDS).Med Hypotheses. 2010 Mar;74(3):513-20. doi: 10.1016/j.mehy.2009.10.008. Epub 2009 Nov 14. Med Hypotheses. 2010. PMID: 19914781
-
Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: the additive and subtractive effect of the three dopaminergic genes--DRD2, D beta H, and DAT1.Am J Med Genet. 1996 May 31;67(3):264-88. doi: 10.1002/(SICI)1096-8628(19960531)67:3<264::AID-AJMG4>3.0.CO;2-N. Am J Med Genet. 1996. PMID: 8725745
Cited by
-
Examining how and why polygenic dopamine composite levels moderate adolescents' vulnerability to peer victimization.Child Adolesc Psychiatry Ment Health. 2022 Nov 17;16(1):84. doi: 10.1186/s13034-022-00521-7. Child Adolesc Psychiatry Ment Health. 2022. PMID: 36397091 Free PMC article.
-
The association of genetic polymorphisms within the dopaminergic system with nicotine dependence: A narrative review.Heliyon. 2024 Jun 15;10(12):e33158. doi: 10.1016/j.heliyon.2024.e33158. eCollection 2024 Jun 30. Heliyon. 2024. PMID: 39021905 Free PMC article. Review.
-
Altered neurocircuitry in the dopamine transporter knockout mouse brain.PLoS One. 2010 Jul 9;5(7):e11506. doi: 10.1371/journal.pone.0011506. PLoS One. 2010. PMID: 20634895 Free PMC article.
-
Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability.Curr Neuropharmacol. 2010 Dec;8(4):335-58. doi: 10.2174/157015910793358123. Curr Neuropharmacol. 2010. PMID: 21629442 Free PMC article.
-
Genetic variants and cognitive functions in patients with brain tumors.Neuro Oncol. 2019 Oct 9;21(10):1297-1309. doi: 10.1093/neuonc/noz094. Neuro Oncol. 2019. PMID: 31123752 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous